Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

BACKGROUND: Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This net...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Huang‐Chih, Wang, Chin‐Chou, Tseng, Chia‐Cheng, Huang, Kuo‐Tung, Chen, Yu‐Mu, Chang, Yu‐Ping, Lai, Chien‐Hao, Fang, Wen‐Feng, Lin, Meng‐Chih, Chuang, Hung‐Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643796/
https://www.ncbi.nlm.nih.gov/pubmed/37737541
http://dx.doi.org/10.1111/1759-7714.15111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643796/
https://www.ncbi.nlm.nih.gov/pubmed/37737541
http://dx.doi.org/10.1111/1759-7714.15111

Ejemplares similares